PureTech Health PLC

NASDAQ:PRTCUnited States

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

Contact Information

Headquarters

6 Tide Street, Suite 400BOSTON, MA, United States 02210

Phone

617-482-2333

Fax

617-482-3337

Executives

Lead Independent Non-Executive Chairman of the Board

Raju Kucherlapati

President, Director

Eric Elenko

Chief Executive Officer, Director

Bharatt Chowrira

Co-Founder, Non-Executive Director

Robert Langer

General Counsel, Company Secretary

Charles Sherwood